Overview

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors

Status:
Recruiting
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche